Joseph D. Hurley

Joseph D. Hurley

Auto-generated profile, based on publicly available information

Joseph D. Hurley

Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Biochemistry
Verified
Journal Article
Closed access
TLThomas J. Lawton
Thomas J. Lawton
GKGrace E. Kenney
Grace E. Kenney
JHJoseph D. Hurley
Joseph D. Hurley
ARAmy C. Rosenzweig
Amy C. Rosenzweig

1 July 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SRSoo Y. Ro
Soo Y. Ro
MRMatthew O. Ross
Matthew O. Ross
YDYue Wen Deng
Yue Wen Deng
SBSharon Batelu
Sharon Batelu
TLThomas J. Lawton
Thomas J. Lawton
ARAmy C. Rosenzweig
Amy C. Rosenzweig
Particulate methane monooxygenase (pMMO) is a copper-dependent integral membrane metalloenzyme that converts methane to methanol in methanotrophic bacteria. Studies of isolated pMMO have been hindered by loss of enzymatic activity upon its removal from the native membrane. To characterize pMMO in a membrane-like environment, we reconstituted pMMOs from Methylococcus (Mcc.) capsulatus (Bath) and Methylomicrobium (Mm.) alcaliphilum 20Z into bicelles. Reconstitution into bicelles recovers methane oxidation activity lost upon detergent solubilization and purification without substantial alterations to copper content or copper electronic structure, as observed by electron paramagnetic resonance (EPR) spectroscopy. These findings suggest that loss of pMMO activity upon isolation is due to removal from the membranes rather than caused by loss of the catalytic copper ions. A 2.7 Å resolution crystal structure of pMMO from Mm. alcaliphilum 20Z reveals a mononuclear copper center in the PmoB subunit and indicates that the transmembrane PmoC subunit may be conformationally flexible. Finally, results from extended X-ray absorption fine structure (EXAFS) analysis of pMMO from Mm. alcaliphilum 20Z were consistent with the observed monocopper center in the PmoB subunit. These results underscore the importance of studying membrane proteins in a membrane-like environment and provide valuable insight into pMMO function.

7 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJung-Eun Shin
Jung-Eun Shin
MSMeredith A. Skiba
Meredith A. Skiba
GNGenevieve R. Nemeth
Genevieve R. Nemeth
JHJoseph D. Hurley
Joseph D. Hurley
AKAndrew C. Kruse
Andrew C. Kruse
Antibodies are essential biological research tools and important therapeutic agents, but some exhibit non-specific binding to off-target proteins and other biomolecules. Such polyreactive antibodies compromise screening pipelines, lead to incorrect and irreproducible experimental results, and are generally intractable for clinical development. Here, we design a set of experiments using a diverse naïve synthetic camelid antibody fragment (nanobody) library to enable machine learning models to accurately assess polyreactivity from protein sequence (AUC > 0.8). Moreover, our models provide quantitative scoring metrics that predict the effect of amino acid substitutions on polyreactivity. We experimentally test our models’ performance on three independent nanobody scaffolds, where over 90% of predicted substitutions successfully reduced polyreactivity. Importantly, the models allow us to diminish the polyreactivity of an angiotensin II type I receptor antagonist nanobody, without compromising its functional properties. We provide a companion web-server that offers a straightforward means of predicting polyreactivity and polyreactivity-reducing mutations for any given nanobody sequence.

14 May 2024 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MSMeredith A. Skiba
Meredith A. Skiba
SSSarah M. Sterling
Sarah M. Sterling
SRShaun Rawson
Shaun Rawson
SZShuhao Zhang
Shuhao Zhang
HXHuixin Xu
Huixin Xu
AKAndrew C. Kruse
Andrew C. Kruse

10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana Granados
Alyana Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.

23 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana J. Granados
Alyana J. Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.